Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8770)
All Articles published online
|
Publishing Process of This Article
|
Jan 21, 2017 (publication date) through Mar 31, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425 [PMID: 28210077 DOI: 10.3748/wjg.v23.i3.414] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i3/414.htm |
| Number | Citing Articles |
| 1 |
Tommaso Trenti, Alessandra Melegari, Chiara Bonaguri. Clinical and Laboratory Medicine Textbook. 2023; : 489 doi: 10.1007/978-3-031-24958-7_36
|
| 2 |
Jean-François Jourdil, Benjamin Némoz, Elodie Gautier-Veyret, Charlotte Romero, Françoise Stanke-Labesque. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. Therapeutic Drug Monitoring 2018; 40(4): 417 doi: 10.1097/FTD.0000000000000514
|
| 3 |
Juliette Villemonteix, Valérie Guérin-El Khourouj, Jean-Pierre Hugot, Caroline Giardini, Guislaine Carcelain, Christine Martinez-Vinson. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases. Biologicals 2021; 70: 17 doi: 10.1016/j.biologicals.2021.02.002
|
| 4 |
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, Dario Dilillo, Giulia Rendo, Cecilia Mantegazza, Gian Vincenzo Zuccotti. Biological therapy in pediatric age. Pharmacological Research 2020; 161: 105120 doi: 10.1016/j.phrs.2020.105120
|
| 5 |
Thaise Boeing, Priscila de Souza, Tiago José Bonomini, Luísa Nathália Bolda Mariano, Lincon Bordignon Somensi, Ruth Meri Lucinda, Angela Malheiros, Luísa Mota da Silva, Sérgio Faloni de Andrade. Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. Biomedicine & Pharmacotherapy 2018; 99: 697 doi: 10.1016/j.biopha.2018.01.142
|
| 6 |
Bhairavi Balram, Harshad Joshi, Karen Wong, Karen I. Kroeker, Levinus A. Dieleman, Brendan P. Halloran, Daniel C. Baumgart, Farhad Peerani. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Digestive Diseases and Sciences 2021; 66(11): 3985 doi: 10.1007/s10620-020-06704-6
|
| 7 |
Benjamin Nemoz, David Ternant, Sébastien Bailly, Elodie Gautier‐Veyret, Jean‐François Jourdil, Bruno Bonaz, Françoise Stanke‐Labesque. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology 2019; 85(4): 722 doi: 10.1111/bcp.13845
|
| 8 |
Scott D. Lee, Raina Shivashankar, Daniel Quirk, Haiying Zhang, Jean-Baptiste Telliez, John Andrews, Amy Marren, Arnab Mukherjee, Edward V. Loftus. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Journal of Clinical Gastroenterology 2021; 55(3): 195 doi: 10.1097/MCG.0000000000001396
|
| 9 |
Pepijn W. A. Thomas, Paul K. L. Chin, Murray L. Barclay. A nationwide survey on therapeutic drug monitoring of anti‐tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal 2021; 51(3): 341 doi: 10.1111/imj.14778
|
| 10 |
Mihika B. Dave, Alpa J. Dherai, Devendra C. Desai, Bhamini G. Keny, Dhanashri N. Shetty, Satish Kulkarni, Kiran Peddy, Tester F. Ashavaid. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit. Indian Journal of Gastroenterology 2020; 39(5): 426 doi: 10.1007/s12664-020-01050-x
|
| 11 |
Feifei Han, Xia Zhao, Xiang Li, Liyuan Peng, Weilin Liu, Jianzhong Han. Bovine lactoferricin ameliorates intestinal inflammation and mucosal barrier lesions in colitis through NF-κB/NLRP3 signaling pathways. Journal of Functional Foods 2022; 93: 105090 doi: 10.1016/j.jff.2022.105090
|
| 12 |
Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir, Amit Assa. Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848211068659
|
| 13 |
瑞芳 胡. Clinical Research Progress of Infliximab Combined with Azathioprine in the Treatment of Inflammatory Bowel Disease. Advances in Clinical Medicine 2022; 12(12): 10987 doi: 10.12677/ACM.2022.12121582
|
| 14 |
Manar Matar, Raanan Shamir, Dan Turner, Efrat Broide, Batia Weiss, Oren Ledder, Anat Guz-Mark, Firas Rinawi, Shlomi Cohen, Chani Topf-Olivestone, Ron Shaoul, Baruch Yerushalmi, Shomron Ben-Horin, Amit Assa. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn’s Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. Inflammatory Bowel Diseases 2020; 26(11): 1627 doi: 10.1093/ibd/izz294
|
| 15 |
Ilana Reinhold, Sena Blümel, Jens Schreiner, Onur Boyman, Jan Bögeholz, Marcus Cheetham, Gerhard Rogler, Luc Biedermann, Michael Scharl. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflammatory Intestinal Diseases 2021; 6(1): 38 doi: 10.1159/000511296
|